Definium Therapeutics, Inc.
DFTX
$17.64
-$0.45-2.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -4.32% | 32.42% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.18% | 11.65% | |||
| Operating Income | -4.18% | -11.65% | |||
| Income Before Tax | 25.02% | -57.37% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 25.02% | -57.37% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 25.02% | -57.37% | |||
| EBIT | -4.18% | -11.65% | |||
| EBITDA | -3.91% | -11.65% | |||
| EPS Basic | 36.24% | -56.39% | |||
| Normalized Basic EPS | 36.24% | -56.39% | |||
| EPS Diluted | 36.15% | -56.39% | |||
| Normalized Diluted EPS | 36.24% | -56.39% | |||
| Average Basic Shares Outstanding | 17.60% | 0.63% | |||
| Average Diluted Shares Outstanding | 17.60% | 0.63% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||